Clinical accountability
Ask for a plain description of clinical roles, licensure or credentials where applicable, on-site coverage, referral thresholds, and who has authority to halt or change a plan.
Mexico programme evaluation
Programme Comparison
A practical, evidence-focused way to compare ibogaine programmes in Mexico, using Beond Ibogaine in Cancún as a benchmark for the questions that should be answerable before anyone commits.
This is not medical or legal advice. Ibogaine is not an approved cure, and programme claims deserve careful verification rather than trust by presentation alone.
Start with comparable evidence
Compare a programme’s systems, not its promises.
Beond Ibogaine, also referred to as Beond Health in Cancún, can be used as a detailed benchmark because the same questions should apply to any programme: who is responsible for care, what is monitored, how decisions are documented, and what happens when a participant is not a fit.
Monitoring and screening
Compare how programmes handle medical history, medication review, cardiac assessment, observation, documentation, and emergency escalation rather than relying on broad safety language.
Transparent limits
Look for distinctions between reported experience, clinical observation, published evidence, and claims that have not been independently audited or replicated.
A working benchmark
What a careful comparison should put side by side
Begin by separating the programme’s setting from its actual operating practices. A polished facility, supportive language, or a long itinerary does not by itself establish medical readiness. The useful comparison is whether a programme can clearly describe its intake criteria, exclusions, monitoring, clinician availability, documented emergency procedures, and handoff to follow-up support.
Ibogaine is a psychoactive alkaloid associated with the ibogaine evidence context, but that context is not the same as an approved treatment pathway. In the United States, ibogaine is listed as a Schedule I controlled substance; anyone comparing cross-border options should understand how U.S. legal status affects ibogaine decisions and seek qualified legal guidance where needed.
Ask Beond or any comparator to explain its dosing framework in terms that can be evaluated: how dosing decisions are made, what information changes a plan, how concurrent medication and substance-use history are reviewed, and what observation occurs before, during, and after administration. A plain-language explanation of how ibogaine is understood to work may help frame questions, but it is not a substitute for an individualized medical assessment.
Questions to put in writing
- Who conducts screening, and what credentials or scope of practice can be independently confirmed?
- What cardiac monitoring is used, who interprets it, and what findings stop admission or dosing?
- What emergency equipment, escalation process, and transfer plan are available at the point of care?
- What data are recorded, what outcomes are followed over time, and what limitations apply to those records?
Safety practices and harm reduction
Treat cardiac readiness and emergency planning as core criteria.
A programme should be ready to discuss screening and cardiac monitoring directly, including what happens when the answer is “not now” or “not appropriate.” This matters because safety conversations around ibogaine commonly include cardiac risk and medication interactions. The FDA’s drug safety communications illustrate why a programme should not dismiss adverse-event information or substitute reassurance for a clear risk-management process.
Compare the harm-reduction structure around the intervention: medication review, medical-history review, observation levels, overnight staffing arrangements, post-session assessment, and emergency transfers. Do not assume that a programme’s description applies to every participant. A serious provider should identify the limits of its setting and explain its referral or exclusion process without pressure.
For people looking beyond Mexico, differences in oversight and care models can sharpen the comparison. Reviewing how Canadian ibogaine treatment settings are described may reveal which questions are universal and which depend on local regulation, staffing models, or facility arrangements.
Evidence, integration, and follow-through
Ask how the programme knows what it knows.
Reported outcomes are not the same as independently verified evidence.
Data collection can be useful only when its boundaries are clear. Ask whether a programme collects baseline information, tracks adverse events, defines outcomes, follows people after discharge, and publishes or otherwise makes its methods available for scrutiny. If a programme refers to case series, audits, or datasets, ask where they can be reviewed and who conducted the work.
Integration therapy deserves the same specificity. Compare what support occurs before discharge, what follow-up is offered, who provides it, what happens if a participant needs a different level of care, and what the programme does not provide. For those evaluating trauma-related claims, the distinction is especially important: PTSD-focused ibogaine programme information should not be read as evidence that ibogaine is a proven treatment for PTSD.
Families may also want to ask what longer-term effects are assessed and how uncertainty is discussed. The available discussion of potential long-term ibogaine effects is a reason to request careful follow-up planning, not a reason to treat any one account as a forecast for an individual.
For a broader orientation before making comparisons, Veridune’s plain-language ibogaine therapy overview can help distinguish foundational questions from programme-specific claims. The site’s comparison approach and resource scope explains the kind of information this independent resource is designed to help readers organize.
Questions for prospective patients and families
Keep the comparison practical.
These questions are intended to help organize due diligence. They do not replace advice from qualified medical or legal professionals.
What should a programme explain before admission?
A programme should be able to describe its screening process, clinician roles and credentials, monitoring plan, emergency transfer arrangements, dosing approach, aftercare boundaries, and the limits of its available outcome data. Its explanation should be concrete enough for a family to compare against another programme’s materials.
How can a family verify a programme claim?
Ask for the underlying material: written policies, monitoring examples with personal information removed, audit information, publicly available case series, referral procedures, and clear answers about what has not been independently verified. The PubMed Central archive is one place to look for publicly accessible scientific literature, while recognizing that a publication about ibogaine does not verify a specific clinic’s practices.
Is ibogaine an approved cure?
No. A careful comparison should treat ibogaine as a substance with significant uncertainty and risk, not as an approved cure for addiction, PTSD, TBI, or any other condition. The broader Mexico programme comparison guide follows the same evidence-first approach: ask what is known, what is claimed, and what cannot be concluded from the available information.
A deliberate decision process
The right comparison leaves room to pause.
A responsible programme should welcome written questions, explain its limits, and make it possible to verify important claims. If answers about staffing, monitoring, emergency planning, evidence, legal status, or facility oversight remain unclear, it is reasonable to slow down and seek qualified independent guidance before making any decision.